Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-300 Ointment in Healthy Adult Volunteers
NCT07684937Phase 1Completed
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Nov 2024
01
Overview
Phase 1, randomised, double-blind trial of HL-300 in atopic dermatitis (AD) (4 arms), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Primary endpoint: Safety and Tolerability of HL-300 Ointment at Day 14. Started Jun 2024; status: completed.
02
Drugs
HL-300
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07684937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684937.